Cancer Treatment

Vivos Therapeutics Received FDA 510(k) Clearance for its Flagship DNA Oral Appliance for the Treatment of Obstructive Sleep Apnea On January 4, 2023, Vivos Therapeutics, Inc., a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mil...

ENHERTU or Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody and a cytotoxic topoisomerase I inhibitor. Three components make up this antibody-drug conjugate (ADC):  A topoisomerase inhibitor that is covalently linked...

Blood cancers have seen tremendous advancements in the past few years owing to the dedication of the researchers who are putting their endless efforts just to bring innovation into the lives of suffering patients. These experimentations and their upshots are always brought to us through various platforms, the Ameri...

The development of tumor therapy in cancer immunotherapy has been aided by programmed death receptor-1 and programmed death protein ligand inhibitors. Since its discovery in 1990, the programmed cell death protein 1 receptor (PD-1) receptor has been known to negatively regulate T-cell mediated immune response via i...

Antibody-drug conjugate (ADCs) is a new emerging class of highly potent pharmaceutical drugs, which is a great combination of chemotherapy and immunotherapy. Over the past couple of decades, antibody-drug conjugates have revolutionized the field of cancer chemotherapy. ADCs are composed of 3 parts: an antibody drug...

Lung Cancer presents a heavy health and economic burden in Asia, being the most common form of cancer, with 60% of the world’s lung cancers being diagnosed there. Lung cancer is also present in more than 30% of non-smokers in Asia, specifically in adenocarcinomas, which is a subtype largely defined by oncogenic dri...

The growth and development in the Digital health technologies, such as mobile health (mHealth) apps, electronic health records (EHRs), electronic medical records (EMRs), wearable devices, telehealth, and telemedicine, as well as personalized medicine, have immensely transformed the healthcare industry and its marke...

DePuy Synthes Received FDA Approval for TELIGEN™ System  On October 20, 2022, DePuy Synthes, The Orthopaedics Company of Johnson & Johnson, provides one of the most comprehensive orthopedics portfolios in the world that helps heal and restore movement for the millions of patients, announced that ...

Oncolytic viruses are cancer treatments that employ a natural or reprogrammed virus capable of targeting and killing malignant cells. They are a new class of cancer agents that induce tumor regression by causing immunogenic cell death, inducing preferential replication in tumor cells, and stimulating host antitumor...

Peripheral T-cell Lymphoma (PTCL) is a diverse disorder category that accounts for 10% to 15% of non-Hodgkin lymphomas. Most PTCL subtypes, including PTCL-NOS, AITL, ALCL, enteropathy-type T-cell lymphoma, and extranodal natural killer (NK) cell/T-cell lymphoma, are aggressive (fast-growing) lymphomas. PTCLs are...